Drug Trial Radar · NCT07191028
Alzheimer's Disease THErapy With NEuroaid II
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Feb 2029
Study completion May 2029
Sponsor
- Lead sponsor
- Moleac Pte Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- National University Hospital, Singapore
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.
Conditions
- Alzheimer's Disease Dementia
Interventions
MLC 901Drug
Oral capsule, 2 capsules 3 times a day for 12 months
PlaceboDrug
Oral capsule, 2 capsules 3 times a day for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alzheimer's Disease Assessment Scale-Cognitive Subscale11 (ADAS-Cog11)Time frame: Baseline, Month 6 and Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National University Hospital Singapore
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.